While serum XO activity has not been empirically validated as a biomarker for COVID-19 severity, its metabolic output—xanthine—has been identified through metabolomic profiling as a promising prognostic biomarker (Karvelsson et al., 2025). This evidence concerns the gene XDH and COVID-19.